VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You, Barbara Sennino, Casey W. Williamson, Beverly Felcman, Hiroya Hashizume, Li-Chin Yao, Dana T. Aftab, and Donald M. McDonald

Précis: Cancer cell-targeted therapeutic agents may achieve efficacy in part by also attacking the tumor microenvironment, as illustrated by this study revealing the antiangiogenesis benefits of MET inhibitors in promoting blood vessel regression, in addition to direct effects against tumor cells themselves.

Podoplanin-Positive Fibroblasts Enhance Lung Adenocarcinoma Tumor Formation: Podoplanin in Fibroblast Functions for Tumor Progression
Ayuko Hoshino, Genichiro Ishii, Takashi Ito, Kazuhiro Aoyagi, Yoichi Ohtaki, Kanji Nagai, Hirotaka Sasaki, and Atsushi Ochiai

Précis: Findings define a fibroblast cell type in the perivascular tumor microenvironment that creates a specific niche for tumor progression, suggesting new strategies to block tumor invasion and metastasis.

IL-7 Contributes to the Progression of Human T-cell Acute Lymphoblastic Leukemias
Ana Silva, Angelo B.A. Laranjeira, Leila R. Martins, Bruno A. Cardoso, Jocelyne Demengeot, J. Andres Yunes, Benedict Seddon, and Joao T. Barata

Précis: Blocking IL-7 may constitute an effective therapeutic strategy to improve treatment of an aggressive form of T-cell leukemia.

Memory Type 2 Helper T Cells Induce Long-Lasting Antitumor Immunity by Activating Natural Killer Cells
Masayuki Kitajima, Toshihiro Ito, Damon J. Tunes, Yusuke Endo, Atsushi Onodera, Kahoko Hashimoto, Shinichiro Motohashi, Masakatsu Yamashita, Takashi Nishimura, Steven F. Ziegler, and Toshinori Nakayama

Précis: Cancer immunotherapies that recruit an IL-4-dependent class of memory T helper cells that can activate antitumor natural killer cells may achieve more potent and durable clinical outcomes.
Cancer Research

4799

**CD8⁺ T Cells Regulate Bone Tumor Burden Independent of Osteoclast Resorption**

Kaihua Zhang, Seokho Kim, Viviana Cremasco, Angela C. Hirbe, Deborah V. Novack, Katherine Weilbaecher, and Roberta Faccio

**Précis:** This is the first report analyzing the relative contribution of osteoclasts and immune cells in development of bone metastases.

4809

**Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors**

Stephen R. Mattarollo, Sherene Loi, Helene Duret, Yuting Ma, Laurence Zitvogel, and Mark J. Smyth

**Précis:** This study adds to growing evidence that the therapeutic efficacy of cytotoxic chemotherapy relies upon antitumor contributions of the innate and adaptive immune systems.

4821

**Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response**

Jitka Fucikova, Petra Krailikova, Anna Fialova, Tomas Brtnicky, Lukas Roh, Jirina Bartunkova, and Radek Špíšek

**Précis:** Findings define the qualities of 'immunogenic' cancer cell deaths that chemotherapeutic drugs may need to trigger in order to elicit efficacious clinical responses, with implications for the design of effective regimens of immunochemotherapy.

4834

**Human Neural Stem Cell Transplantation Ameliorates Radiation-Induced Cognitive Dysfunction**

Munjal M. Acharya, Lori-Ann Christie, Mary L. Lan, Erich Giedzinski, John R. Fike, Susanna Rosi, and Charles L. Limoli

**Précis:** Cognitive dysfunction is a common and serious side-effect of radiotherapy in brain cancer patients which the findings of this study suggest might be reversed by stem cell transplantation.

4846

**Engagement of β-1, 6-N-Acetylglucosaminyltransferase 2 in Breast Cancer Metastasis and TGF-β Signaling**

Haijun Zhang, Fanyan Meng, Sherwin Wu, Bas Kreike, Seema Sethi, Wei Chen, Fred R. Miller, and Gueojun Wu

**Précis:** Findings reveal that breast cancer metastasis driven by TGF-β signaling relies upon the activity of a novel glycosyltransferase, identifying a tractable therapeutic target to the development of broad-acting treatments for advanced disease.

4857

**The MeI/Elf4 Transcription Factor Fine Tunes the DNA Damage Response**

Goro Sashida, Narae Baek, Silvana Di Giandomenico, Takashi Asai, Nadia Gurvich, Elena Bazzoli, Yan Liu, Gang Huang, Xinyang Zhao, Silvia Menendez, and Stephen D. Nimer

**Précis:** This mechanistic study shows how a member of the ETS transcription family fine tunes the DNA damage response that is orchestrated by the central regulatory kinase ATM, with implications for understanding cancer susceptibility and chemotherapeutic responses.

4866

**CCI-779 Inhibits Cell-Cycle G2–M Progression and Invasion of Castration-Resistant Prostate Cancer via Attenuation of UBE2C Transcription and mRNA Stability**

Hongyan Wang, Chunpeng Zhang, Anna Borick, Dayong Wu, Ming Chiu, Jennifer Thomas-Ahner, Zhong Chen, Hongyan Chen, Steven K. Clinton, Kenneth K. Chan, and Qianben Wang

**Précis:** This study of the mechanism of action of an mTOR inhibitor defines an androgen receptor target gene that may be a critical driver of advanced prostate cancers.

4877

**Two Novel Determinants of Etoposide Resistance in Small Cell Lung Cancer**

Malcolm H. Lawson, Natalie M. Cummings, Doris M. Rassl, Roslin Russell, James D. Brenton, Robert C. Rintoul, and Gillian Murphy

**Précis:** The identification of two new genes that mediate resistance to etoposide chemotherapy may offer rational strategies to prevent or relieve chemoresistance that causes the demise of patients suffering relapse.

4888

**Notch Signaling in CD66⁺ Cells Drives the Progression of Human Cervical Cancers**

Jeevisha Bajaj, Tessy Thomas Maliekal, Eric Vivien, Chitra Pattabiraman, Sweta Srivastava, H. Krishnamurthy, V. Giri, Deepa Subramanyam, and Sudhir Krishna

**Précis:** This study presents a powerful mechanistic rationale to inhibit Notch signaling as a generalized therapeutic strategy to treat metastatic cancers.
**PREVENTION AND EPIDEMIOLOGY**

4898  Prediagnostic Serum Levels of Cytokines and Other Immune Markers and Risk of Non-Hodgkin Lymphoma
Mark P. Purdue, Qing Lan, Rachel Bagni, William C. Hocking, Dalsu Baris, Douglas J. Reding, and Nathaniel Rothman

*Précis:* This prospective study identifies elevations in serologic markers associated with future risk of non-Hodgkin lymphoma.

**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

4908  SPARC Stimulates Neuronal Differentiation of Medulloblastoma Cells via the Notch1/STAT3 Pathway
Praveen Bhoopathi, Chandramu Chetty, Ranadeer Dontaula, Meena Gujrati, Dzung H. Dinh, Jasti S. Rao, and Sajani S. Lakka

*Précis:* This study suggests a differentiation-inducing strategy to increase therapeutic responses in a commonly deadly form of pediatric brain cancer.

4920  Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly, Johannes M. Heuckmann, Elisa de Stanchina, Heidi Chen, Roman K. Thomas, Chris Liang, and William Pao

*Précis:* Acquired resistance arising in ALK-fusion positive cancers to a first generation ALK tyrosine kinase inhibitor in clinical trials might be addressed by a novel, more potent, and specific second generation inhibitor.

4932  Caveolin-1 Upregulation Mediates Suppression of Primary Breast Tumor Growth and Brain Metastases by Stat3 Inhibition
Wen-Tai Chiu, Hsueh-Te Lee, Feng-Ju Huang, Kenneth D. Aldape, Jun Yao, Patricia S. Steeg, Cheng-Yang Chou, Zhimin Lu, Kepeing Xie, and Suyun Huang

*Précis:* The mediator of brain metastasis identified in this study is likely a core modifier node of many cancer signaling pathways, since it functions in controlling the formation of plasma membrane lipid rafts that organize many cell surface adhesion and signaling complexes.

4944  Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells

*Précis:* An analysis of the checkpoint and DNA repair pathway responses activated by floxuridine reveals how to combine these existing chemotherapeutic agents with PARP inhibitors to achieve the best therapeutic efficacy.

4955  Sorafenib enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells
Antoine Dufour, Nicole S. Sampson, Jian Li, Cem Kuscu, Robert C. Rizzo, Jennifer L. DeLeon, Jizu Zhi, Nadia Jaber, Eric Liu, Stanley Zucker, and Jian Cao

*Précis:* Although early MMP inhibitors moved into clinical development were not successful, the central importance of MMPs in cancer invasion and metastasis has driven the development of later generation inhibitors that offer considerable therapeutic potential.
### TUMOR AND STEM CELL BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>4989</td>
<td>Positive Feedback Loop Between PI3K-Akt-mTORC1 Signaling and the Lipogenic Pathway Boosts Akt Signaling: Induction of the Lipogenic Pathway by a Melanoma Antigen</td>
<td>Yoshio Yamauchi, Keiko Furukawa, Kazunori Hamamura, and Koichi Furukawa</td>
<td>Précis: This study suggests a mechanistic explanation for why cancer cells synthesize high levels of cholesterol and fatty acids, which by promoting formation of plasma membrane lipid rafts can reinforce signaling events that sustain cancer cell survival.</td>
</tr>
<tr>
<td>4998</td>
<td>Suppression of Apoptosis by PIF1 Helicase in Human Tumor Cells</td>
<td>Mary E. Gagou, Anil Ganesh, Ruth Thompson, Geraldine Phear, Cyril Sanders, and Mark Meuth</td>
<td>Précis: Findings define the function of a DNA helicase that is crucial for the viability of cancer cells under DNA replication stress, with potential implications for how to increase cancer chemosensitivity.</td>
</tr>
<tr>
<td>5009</td>
<td>Notch Signaling Activated by Replication Stress–Induced Expression of Midkine Drives Epithelial–Mesenchymal Transition and Chemoresistance in Pancreatic Cancer</td>
<td>Cenap Gungör, Hike Zander, Katharina E. Efrenberger, Yogesh K. Vashist, Tatyana Kalinina, Jakob R. Izbicki, Emre Yekebas, and Maximilian Bockhorn</td>
<td>Précis: Findings suggest that overexpression of the growth factor Midkine plays a role in the inherent chemoresistance of pancreatic cancer cells, suggesting that depleting this factor might heighten their sensitivity to chemotherapy.</td>
</tr>
<tr>
<td>5020</td>
<td>STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis</td>
<td>Ryan B. Corcoran, Gianmarco Contino, Vikram Deshpande, Alexandros Tzatsos, Claudia Conrad, Cyril H. Benes, David E. Levy, Jeffrey Settleman, Jeffrey A. Engelman, and Nabeel Bardeesy</td>
<td>Précis: Findings show that JAK2-STAT3 signaling is required for pancreatic cancer initiation, progression, and maintenance, and that this pathway predicts the response to JAK2 inhibitors in clinical development.</td>
</tr>
</tbody>
</table>

### LETTERS TO THE EDITOR

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>5052</td>
<td>Myeloid Suppressor Cells Regulate the Lung Environment—Response</td>
<td>Hannah H. Yan, Michael Pickup, Yanli Pang, Agnieszka E. Gorska, Zhanyang Li, Anna Chytel, Yipeng Geng, Jerome W. Gray, Harold L. Moses, and Li Yang</td>
<td></td>
</tr>
</tbody>
</table>

### CORRECTION

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>5054</td>
<td>Correction: Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Tumor antigen-reactive CTLs by programming iPS cells infiltrated into tumor tissue. Tumor antigen TCR gene-transduced iPS cells were adoptively transferred into C57BL/6 mice, which were subjected to challenge with E. G7 tumor cells. On day 35 after tumor challenge, tumor tissues were examined for tumor-reactive T-cell infiltration by immunohistological staining. Tumor antigen-specific CTLs (red) infiltrated into lymphoma tissue (green). For details, see the article by Lei and colleagues on page 4742 of this issue.